Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Autism Spectrum Disorder: A Mini Review

 

Kovardini Anandhi Jayavelu, Venkateswaramurthy N*

Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy,

Kumarapalayam, Namakkal, Tamil Nadu, India.

*Corresponding Author E-mail: nvmurthi@gmail.com

 

ABSTRACT:

Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder affecting approximately 1 in 100 children worldwide. Existing pharmacological interventions targeting ACE2 or other immune-related agents have not yet undergone largescale analysis. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are a novel, ethically supported, immunomodulatory therapeutic that may engage these central biological mechanisms. Objective: To perform a review of the safety, clinical efficacy, mechanistic basis and routes of administration of UC-MSC therapy and associated cell-free products in children with ASD. Methods and materials: A detailed literature search was conducted using PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov. gov through the first half of November 2025. Clinical and preclinical studies assessing UCMSCs or products derived from these cells (including exosomes) in paediatric ASD and similar neurological disorders were identified. Eligible randomised controlled trials (RCTs) and observational studies published in English, reporting safety and/or efficacy measures, were narratively synthesised by safety profile, clinical efficacy, the mechanistic data on which they relied, and route of administration. Results: Safety profiles were favourable in all phase I/II trials and case reports, with no serious adverse events observed with the treatment; transient, self-limited reactions were observed. Clinically meaningful improvements, defined as such based on standardised measures CARS, ATEC and adaptive behaviour scales, were noted in approximately 40–50% of treated subjects. Mechanistic evidence supports systemic immunomodulation, reduced neuroinflammation, restoration of the excitatory–inhibitory balance, and paracrine neurotrophic signalling. Novel cell-free candidates have emerged, among them UC-MSC-derived exosomes. Conclusions: UC-MSC therapy is feasible and well-tolerated with promising early efficacy signals. Nevertheless, validating these findings in rigorously designed double-blind randomised controlled trials with biomarker-based patient stratification will be essential before wider clinical application.

 

KEYWORDS: Umbilical cord mesenchymal stem cells, Autism spectrum disorder, Cell therapy, Immunomodulation, Neuroinflammation, Regenerative medicine.

 

 


INTRODUCTION:

Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy represents an innovative approach under investigation for the treatment of autism spectrum disorder (ASD), a neurodevelopmental condition. The World Health Organisation estimates that approximately 1 in 100 children is affected by ASD, a significant public health challenge worldwide1. As the need for effective treatments has increased alongside the refinement of prevalence rates2.While current standards of care, mainly behavioural and educational interventions2. provide valuable support, they do not address the core pathophysiology for all individuals. The gap in ASD is a lack of mechanisms, long-term safety data, and long-term evidence in the paediatric population3. Recently, many researchers have been studying umbilical cord mesenchymal stem cell therapy. Therefore, rigorous research is needed before umbilical cord-derived mesenchymal stem cell (UCMSC) therapy can be considered a validated treatment option. It has emerged as a prominent, ethically uncontroversial area of research. The use of UC-MSCs is justified by the evidence linking neuroinflammation and immune dysregulation to the etiology of ASD2. Starting with an examination of its suggested mechanisms of action, such as immunomodulatory, anti-inflammatory, and neurotrophic effects3. The available clinical data from trials carried out globally to assess the effectiveness of treatment for core and related ASD symptoms will then be critically compiled4. The safety profile of UC-MSC administration, which is of almost equal importance in paediatric populations, will be the primary focus. To assess the effectiveness of this experimental therapy, this review will conclude by examining current safety data, evidence, and promising future directions. The safety profile of UC-MSC limitation in paediatric populations. This review aims to discuss the current limitations and promising future direction necessary to determine whether this experimental therapy can one day become a validated treatment for individuals with autism spectrum disorder.

 

METHODOLOGY:

A comprehensive literature search was conducted across multiple electronic databases, including PubMed/ MEDLINE, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov, from inception through November 2025. The search strategy employed a combination of Medical Subject Headings (MeSH) terms and free-text keywords including "umbilical cord mesenchymal stem cells," "UC-MSCs," "Wharton's jelly stem cells," "cord blood mononuclear cells," "autism spectrum disorder," "ASD," "neurodevelopmental disorders," and "cell therapy." Boolean operators (AND/OR) were used to combine search terms systematically. The reference lists of eligible studies and relevant review articles were manually screened to identify additional publications not captured in database searches. Two independent reviewers conducted the initial screening of titles and abstracts, followed by fulltext assessment for eligibility; discrepancies were resolved through consensus or consultation with a third reviewer. Studies were included if they:1.investigated umbilical cord-derived mesenchymal stem cells or related cellular products (including exosomes) in human subjects or validated preclinical models; 2.reported safety and/or efficacy outcomes relevant to autism spectrum disorder or analogous neurological conditions;3.were published in peer-reviewed journals in English; and4 provided sufficient methodological detail for quality assessment. Exclusion criteria comprised conference abstracts without full-text availability, editorials, narrative reviews, and studies that used exclusively non-umbilical cord-derived cell sources. Data extraction was performed using a standardized form that captured study design, population characteristics, cell type, dosage, administration route, follow-up duration, safety profile, efficacy outcomes, and mechanistic findings. Given the heterogeneity in study designs, cell preparations, dosing regimens, and outcome measures across included studies, a qualitative narrative synthesis was conducted rather than meta-analysis, with findings organized thematically by safety profile, clinical efficacy, mechanistic considerations, and administration routes.

 

CLINICAL SAFETY PROFILE:

SAFETY IN PEADATRIC ASD POPULATION:

The clinical applicability of UC-MSC therapy for autism spectrum disorder needs to be established primarily through a demonstrable safety profile, which is critically important due to the fact that it will involve the pediatric population. Overall, available data from Phase I/II clinical trials are consistent with the safety profile and lack of toxicity of UC-MSC treatment across a variety of treatment models and delivery routes. According to the initial Phase I/II open-label clinical trial from which the current cohort was derived, the UC-MSCs combined with CBMNC treatment showed an acceptable safety profile; all treated individuals (N=23) were free from severe adverse events, immune reactions, or organ toxicity; only transient mild fever was seen in 21.7% of cases and resolved spontaneously without specific medical managemen1. This favorable safety profile has been confirmed in subsequent studies. Sun et al. reported a strong safety profile in their phase I open-label trial (IV) of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSCs) after infusion into 12 children with ASD. The therapeutic intervention was well tolerated across the entire population studied, with no serious AEs.6 The most significant biological response was the occurrence of asymptomatic, class I anti-HLA antibodies in 42% of participants (without clinical consequences), consistent with no clinically pertinent immune rejection after allogeneic UCMSC infusion.6 Furthermore, the phase I/II longitudinal study by Riordan et al. used a strict high-frequency regimen of four i.v. infusions every 9 months, and demonstrated a complete lack of safety concern regarding treatment-related serious adverse event (SAE) (all SAE were reported as mild to moderate, transient7.This safety profile has been supported by case reports of even more aggressive treatment schedules. Lee et al. demonstrated that patients receiving >1 × 10⁶ cells/kg in multiple intravenous infusions (4-6doses) at the same concentration were safe; no acute adverse reactions, such as hypersensitivity, were observed, and no delayed toxicity, such as tumorigenesis, was observed8.  Thepreliminary study of Kabatas et al. using twice chlorotoxin-armed MV roped by intravenous and intrathecal infusions in six rounds achieved 100% safety with no severe side effects or tumorigenicity reported through a complete follow up of 2 years9. Even in more complex regenerative approaches that use multiple MSC sources and delivery methods, Gesundheit et al. indicate that exosomes were well tolerated during a 3.5-year follow-up period, with only transient fever and shivering observed after an exosome transfusion.

 

SUPPORTING EVIDENCE FROM THERAPEUTIC AREA:

These UC-MSC safety trials in similar neurological and systemic indications have therefore provided the necessary validation evidence for pediatric neuroregenerative interventions. Yusuf et al. demonstrated 100% safety and tolerability rate within 30 days post infusion (C/M) without significant impact on tumor markers immunoassay, including carcinoembryonic antigen, carbohydrate antigen 19-9 (p=0.89), eosinophilia counts (stable eosinophil count, p=0.08), and inflammation spikes[including stable albumin/globulin ratio C/M p=0.68]2.Remarkably, this study observed that not only was there a statistically significant amelioration of liver diseases by decreased alanine aminotransferase (p=0.04) and gammaglutamyl transferase levels (p=0.01), but also the use of UC-MSC infusion is unable to cause toxicity at the systemic level 2 .The Phase I/II dose-finding trial by Jamali et al. in a series of MS patients (N=35) provides strong evidence for high-dose combined intrathecal and IV protocols, with 100% safety, including no severe AEs or tumorigenicity, over the 12-month observation period, without bacterial meningitis or significant immune rejection 4 .The study of the Phase I/II randomized double-blind, placebo-controlled Zhu et al. (N=30), who were primarily interested in frailty of aging, had 100 % safety about SAE without any difference in adverse events between treatment and placebo Groups during a 6-month follow-up, which proved again that allogeneic UCMSCs display low immunogenicity11.

 

SAFETY OF ANDROGENS VIA NEW DELIVERY ROUTES AND CELL-FREE FORMS:

The safety of intrathecal delivery (direct access to the central nervous system) has been confirmed in multiple studies. The multicenter, open-label study by Sharma et al. (N=254) using intrathecal cell transplantation reported a 98% safety profile for severe adverse events, despite minor procedure-related side effects (spinal pain [7.48%] and headache [3.54%]); clinically relevant complications were rare12.The Phase I study of Avertacker by Bydon et al. among spinal cord injury subjects receiving UC-MSCs, no serious adverse events were linked with the administration of the product over a 2-year follow-up, and only transient headaches and musculoskeletal pain were seen in 80% of patients, which is more likely due to the lumbar puncture process than related to the cell product 13.

 

Cell-free methods using MSC-derived exosomes have potential as a novel modality, given their safety advantages. The phase I dose-escalation trial of Akhlaghpasand et al. using human allogeneic umbilical cord mesenchymal stem cell-derived exosomes in intrathecal treatment was found to be 100% completely safe and tolerable, with no early or late adverse events occurring during a thorough follow-up of 12 month5. This finding indicates that cell-free exosome-based strategies provide a low-immunogenic strategy without the potential adverse effect.

 

THERAPEUTIC EFFICACY:

RESPONSE RATES AND CLINICAL EFFICACY:

The clinical effects of UC-MSC therapy in patients with ASD were assessed using standardised psychometric tests: The Childhood Autism Rating Scale (CARS), Autism Treatment Evaluation Checklist (ATEC), Aberrant Behavior Checklist (ABC), and Vineland Adaptive Behavior Scales (VABS). The initial trial of UC-MSCs combined with cord blood mononuclear cells demonstrated that this combination produced better therapeutic effects than CBMNCs or control rehabilitation, as evidenced by significant reductions in CARS and ABC scores1.The authors believed that the beneficial effects were likely to result from the synergistic interaction between the strong immunomodulatory effects of UC-MSCs and the proangiogenic effects of CBMNC on cerebral hypoperfusion1. Quantitative efficacy data have been particularly impressive in case series and small cohorts. Lee et al. reported a dramatic decrease in CARS score from 43.25 to 31.25, exceeding the standard threshold for clinically significant improvement (i.e., at least a 10-point change), with corresponding improvements in social communication, eye contact, and affect modulation3. The pilot study conducted by Kabatas et al. also described a decrease in CARS score from 37 to 31 with significant improvements in developmental age measurements, according to the Denver II assessment, language capacities advanced from 26 months to 45 months9.  Perhaps most revelatory, Gesundheit et al. reported a normalisation of ATEC score from 149 (severe) at baseline to 15 (within normal range) after treatment, in addition to a decrease in the Social Responsiveness Scale-2 (SRS-2; a measure of autism severity score) from 193 to 32, which was biologically confirmed with the disappearance of epileptiform discharges on EEG10.

 

The response rates in larger cohorts are of significant clinical benefit to the number of patients treated. The Phase I/II trial by Riordan et al. (N=20) recorded evidence for therapeutic response in 40% of the control group (8 individuals were classified as responders, with highly significant changes reported on both CARS and ATEC; three of these had an improvement from "severe" to well below the diagnosis cut-off for autism7.Sun et al. found that 50% (6/12) of their cohort showed clear improvement on at least 2 ASD-targeted outcome measures at 12months post-intervention6.The comprehensive study of Sharma et al. (N=254) showed significant gains in ISAA and CARS scores12. The summary of clinical evidence for Mesenchymal Stem Cell Therapy in Autism Spectrum Disorder and Related Conditions was tabulated in Table 1.

 

OBJECTIVE BIOMARKERS OF EFFICACY:

In addition to subjective behavioural scales, some trials have also used objective biomarkers to assess treatment efficacy. Dawson et al. reported a phase I study of autologous umbilical cord blood with Eye Gaze Tracking (EGT), and found that odds of attending to social stimuli increased by 20% over time (OR = 1.20, p=0.048), offering an objective biomarker for enhanced social attention 3.The VABS-II Socialization Standard Score significantly improved from baseline to 6 months (P II open-label trials and case series;>single-arm studies. Several authors have stressed the urgent need for large-scale, appropriately powered RCTs to confirm preliminary efficacy signals statistically and to distinguish biological from placebo effects.3,6,8,9. The finding of significant placebo responses in ASD trials, as reported by Yamasue et al. in the RCT of oxytocin, acts as an essential methodological consideration that highlights the importance of blinded placebo-controlled designs16. Functional polymorphisms in the Macrophage Migration Inhibitory Factor (MIF) gene promoter demonstrated significant genetic association with behaviors related to autism spectrum disorder across separate family cohorts. Individuals diagnosed with autism displayed increased plasma levels of MIF, and these elevated concentrations were found to correlate with a greater severity of autism symptoms, indicating that MIF may serve as a potential biomarker for susceptibilit17. Genes associated with high confidence for ASD exhibit convergent expression patterns in the mid-fetal cortical layer 5/6 projection neurons. This observation suggests a crucial developmental period and a specific neuronal cell type that play significant roles in the pathophysiology of ASD18. A variety of genetic, neurological, metabolic, immune, and physiological biomarkers demonstrate potential for the early diagnosis and treatment monitoring of ASD; however, the majority have not been adequately validated for regular clinical application19. Children diagnosed with ASD exhibit altered adaptive immune responses, characterized by irregular cytokine production and diminished T-cell activation.

 

These alterations are associated with the extent of behavioral and developmental challenges.

 

CELL-FREE APPROACHES:

The application of cell-free exosome‐based therapies in the future would hold great promise, as they offer several advantages over whole‐cell transplantation, including reduced immunogenicity, easier and more reliable production and storage, and greater conformity with quality control standards. The First-in-Human study by Akhlaghpasand et al. demonstrated the safety and feasibility of such an approach5.From Liang and colleagues, evidence has recently been reported in preclinical studies. offers proof of concept for a non-invasive, safer, and highly targeted intranasal exosome protocol as an alternative for potential clinical translation14.These discoveries suggest the cell-free modalities can be considered as next-generation strategies for MSC-based therapies in ASD.

 

PATIENT STRATRIFICATION AND PRECISION MEDICINE:

Genetic and molecular diversity of ASD indicates that stratification of patients is likely to be critical in maximizing the response to therapy. Gaugler described that autism shows approximately 52% narrow-sense heritability, primarily attributable to common genetic variants. In contrast, rare de novo mutations have a substantial impact on individual risk but account for only a modest portion of total liability variance (around 2.6%)21,22. Mapping the physical and genetic interaction networks of genes associated with neuropsychiatric disorders can link genomic findings to functional pathways and clinical neurobiology, thereby facilitating a better understanding of disease mechanisms and therapeutic insights23.The identification by Ramaswami et al. of a convergent molecular subtype, defined by the "immune-up/neuronal-down" axis, in approximately two-thirds of ASD patients provides a method for identifying patients with the highest probability of benefiting from immunomodulatory intervention24 .This discrepancy in numbers between 53 ASD-enriched genes and 49 broader neurodevelopmental delay-linked genes reported by Satterstrom et al may inform patient selection25 . The finding that the therapeutic effects in the Dawson et al. trial were more evident in children with a higher nonverbal IQ. This result may indicate that the effect can be predicted by initial characteristics

 

 

COMBINATION THERAPIES:

Synergistic effects between UC-MSCs and C-MNC1 indicated the potential of combination therapy for better efficacy. Comments The possibility of MSC-derived paracrine signaling to augment or sustain endogenous oxytocinergic system activity, as indicated by the study of Yamasue et al. trial showing marked changes in behaviour following intranasal oxytocin19. suggests the potential to add pharmaceutically based interventions to cell - based approaches.


 

Ref

Author/Year

Study Design

N

Cell Type

Route

Dose/Protocol

Safety Outcomes

Efficacy Outcomes

[1]

Lv et al.

Phase I/II Open-label

23

UC-MSC + CBMNC

IV + IT

4 weekly infusions

100% free of SAEs; 21.7% transient fever

Significant ↓ CARS and ABC vs controls

[8]

Lee et al. 2020

Case Study

2

UC-MSC (WJ)

IV

4-6 doses; 1×10⁶ cells/kg

100% safety; no AEs

CARS: 43.25→31.25; ↑ social function

[9]

Kabatas et al. 2025

Pilot Study

1

WJ-MSC

IV + IT

6 sessions; 1×10⁶ cell/kg/route

100% safety at 2-year F/U

CARS: 37→31; Language: 26→45

[3]

Dawson et al. 2017

Phase I Open-label

25

Autologous UCB

IV

Single; 1-5×10⁷ cells/kg

No SAEs; 20% mild allergic

↑ VABS-II (p<0.05); ↑ eye gaze (OR 1.20)

[10]

Gesundheit et al. 2025

Case Report

1

PD-MSC + UC-MSC + Exosomes

IV + IM + IN

5 courses over 3.5 years

1 transient fever; no SAEs

ATEC: 149→15; SRS-2: 193→32; EEG normalized

[6]

Sun et al. 2020

Phase I Open-label

12

hCT-MSC

IV

1-3 doses; 2×10⁶ cells/kg q2mo

100% SAE-free; 42% HLA Ab (asymptomatic)

50% improved ≥2 outcome measures

 

[7]

Riordan et al. 2019

Phase I/II Single-arm

20

UC-MSC

IV

4 infusions; 36×10⁶ cells q12wk

100% SAE-free; mild transient AEs

40% responders; 3 below ASD threshold; ↓MDC/TARC

[12]

Sharma et al. 2020

Open-label

254

BM-MNC

IT

Multiple IT injections

98% SAE-free; 7.5% spinal pain; 1.97% seizures

Significant ↓ ISAA and CARS; normalized PET-CT

[2]

Yusuf et al.

Phase I Case Series

9

UC-MSC

IV

Single infusion

100% tolerability; no tumor markers Δ (p=0.89)

↓ ALT (p=0.04); ↓ GGT (p=0.01)

[4]

Jamali et al. 2024

Phase I/II Dose-finding

35

UC-MSC + Secretome

IV + IT

Up to 150×10⁶ cells

100% SAE-free at 12-mo F/U

↓ TNF-α, TAP-1, miR142; ↑ CD3+CD4+

[5]

Akhlaghiapsand et al. 2024

Phase I FIH

9

UC-MSC Exosomes

IT

300 µg exosomal protein

100% tolerability; no AEs at 12 mo

Functional recovery (p<0.05)

[11]

Zhu et al. 2024

Phase I/II RCT

30

UC-MSC

IV

2 doses; 1×10⁶ cells/kg

100% SAE-free; no diff vs placebo

↓ TNF-α (p=0.034); ↓ IL-17 (p=0.033)

[15]

Tsuji et al. 2023

Preclinical (LBW rat)

N/A

Human UC-MSC

IV

1×10⁵ cells P1

100% tolerability; no toxicity

Restored E/I balance; ↓ hyperexcitability

[13]

Bydon et al. 2024

Phase I Open-label

10

AD-MSC

IT

Single; 1×10⁸ cells

100% SAE-free at 2-yr F/U

70% AIS improvement; ↑ CSF VEGF

[14]

Liang et al. 2020

Preclinical (VPA mouse)

N/A

UC-MSC Exosomes

IN

Intranasal exosomes

100% safety; no immunotoxicity

Reversed social deficits; ↓ IL-1β TNF-α, IL-6

 

 


A plethora of multi-modal protocols, including various cell sources, delivery routes, and exosome supplementation, was used by Gesundheit et al10. warranting further systematic investigation.

 

CONCLUSION:

Umbilical cord mesenchymal stem cell therapy demonstrates feasibility and potential efficacy, providing a disease-modifying treatment strategy for autism spectrum disorder. Collective clinical, mechanistic, and genetic evidence supports these findings. The safety profile is consistently favorable across trials and delivery modes, with no severe or life-threatening AEs attributed to the cells. Signals of efficacy, such as clinically meaningful reductions in standardised autism assessments, are observed in 40-50% of treated cohorts, with some trial participants achieving substantial normalisation of phenotypes. Its therapeutic mechanism appears to be driven primarily by systemic immunomodulation that modulates neuroinflammatory cascades, accompanied by paracrine signalling via neurotrophic factors and, likely, by a reinstatement of the excitatory-inhibitory equilibrium, which together results in symptom amelioration. This mechanistic profile is consistent with the known pathophysiology of ASD, including the convergent immune activation and synaptic abnormality molecular subtype, the polygenic genetic architecture of ASD that predicts sensitivity to multi-target treatments, and the established discordant immunity in these individuals. Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014;46(8):881-885. doi:10.1038/ng.3039 There are still notable gaps that should be addressed by high-quality randomized trials with sufficient sample sizes and blinding to ultimately confirm efficacy. Future research should focus on establishing validated biomarkers for patient stratification and therapy monitoring, refining in vivo routes of administration and therapeutic doses, and exploring cell-free exosome-based strategies. This confluence of a favorable safety profile, encouraging efficacy signals, a strong biological rationale, and improved manufacturability positions UC-MSC therapy as a leading candidate to become the first-ever cell-based disease-modifying treatment for ASD.

 

REFERENCES:

1.      Lv Y, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord–derived mesenchymal stem cells in autism. J Transl Med. 2013; 11: 196

2.      Yusof B, Kamal I, Lee KM, et al. A case series on safety and tolerability of human umbilical cord–derived mesenchymal stem cells in patients in Malaysia. SAGE Open Med Case Rep. 2024; 12: 1-6. doi:10.1177/2050313X241299422

3.      Dawson G, Sun JM, Davlantis K, et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial. Stem Cells Transl Med. 2017; 6(7): 1332-1339. doi:10.1002/sctm.16-0474 IF: 4.9 Q2

4.      Jamali F, Aldughmi M, Atiani S, et al. Human umbilical cord–derived mesenchymal stem cells in the treatment of multiple sclerosis patients: phase I/II dose-finding clinical study. Cell Transplant. 2024; 33: 1-18. doi:10.1177/09636897241233045

5.      Akhlaghiapsand M, Tavanaei R, Hosseinpoor M, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell– derived exosomes in complete subacute spinal cord injury: a first-in-human, singlearm, open-label, phase I clinical trial. Stem Cell Res Ther. 2024; 15: 264. doi:10.1186/s13287-024-03868-0

6.      Sun JM, Dawson G, Franz L, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020; 9(10): 1137-1146. doi:10.1002/sctm.19-0434

7.      Riordan NH, Hincapié ML, Morales I, et al. Allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels. Stem Cells Transl Med. 2019; 8(10): 1008- 1016. doi:10.1002/sctm.19-0010

8.      Lee SY, Ahn H, Jung WJ, Ahn J, Lee KH. A case study on autism spectrum disorder treatment using allogenic mesenchymal stem cells derived from the human umbilical cord. Case Rep Open Access. 2020; 5: 1-7

9.      Kabatas S, Civelek E, Savrunlu EC, et al. Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. World J Methodol. 2025; 15(1): 98557. doi:10.5662/wjm.v15.i1.98557

10.   Gesundheit B, Hochbaum L, Fetyukhina A, Vorobyev V, Vorobyev N. Mesenchymal stromal cell treatment alleviates autism spectrum disorder symptoms: a case report. Cureus. 2023; 17(5): e83440. doi:10.7759/cureus.83440 I

11.   Zhu Y, Huang C, Zheng L, et al. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. Stem Cell Res Ther. 2024; 15: 122. doi:10.1186/s13287-024-03707-2

12.   Jamali AK, Gokulchandran N, Kulkarni P, et al. Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study. Am J Stem Cells. 2020; 9(5): 89-100

13.   Bydon M, Qu W, Moinuddin FM, et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial. Nat Commun. 2024; 15: 2201. doi:10.1038/s41467-024-46259-y

14.   Liang Y, Duan L, Xu X, et al. Mesenchymal stem cell-derived exosomes for treatment of autism spectrum disorder. ACS Appl Bio Mater. 2020; 3(9): 6384-6393

15.   Tsuji M, Mukai T, Sato Y, et al. Umbilical cord–derived mesenchymal stromal cell therapy to prevent the development of neurodevelopmental disorders related to low birth weight. Sci Rep. 2023; 13: 8341. doi:10.1038/s41598-023-30817-3

16.   Yamasue H, Okada T, Munesue T, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2020; 25(8): 1849-1858. doi:10.1038/s41380-018-0097-2

17.   Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics. 2008; 122(2): e438-e445. doi:10.1542/peds.2007-3604

18.   Willsey AJ, Sanders SJ, Li M, et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. 2013; 155(5): 997- 1007. doi:10.1016/j.cell.2013.10.020

19.   Jensen AR, Lane AL, Werner BA, et al. Modern biomarkers for autism spectrum disorder: future directions. Mol Diagn Ther. 2022; 26(5): 483-495. doi:10.1007/s40291- 022-00600-7

20.   Ashwood P, Krakowiak P, Hertz-Picciotto I, et al. Altered T cell responses in children with autism. Brain Behav Immun. 2011; 25(5): 840-849. doi:10.1016/j.bbi.2010.09.002

21.   Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014; 46(8): 881-885. doi:10.1038/ng.3039

22.   Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with           autism. Nature. 2012; 485(7397): 237-241. doi:10.1038/nature10945

23.   Willsey AJ, Morris MT, Wang S, et al. The psychiatric cell map initiative: a convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. Cell. 2018; 174(3): 505-520. doi:10.1016/j.cell.2018.06.016

24.   Ramaswami G, Won H, Gandal MJ, et al. Integrative genomics identifies a convergent molecular subtype that links epigenomic with transcriptomic differences in autism. Nat Commun. 2020; 11(1): 4873. doi:10.1038/s41467-020-18526-1

25.   Satterstrom FK, Kosmicki JA, Wang J, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020; 180(3): 568-584.e23. doi:10.1016/j.cell.2019.12.036

 

 

 

 

 

 

Received on 01.07.2026         Revised on 17.08.2026

Accepted on 19.09.2026         Published on 17.10.2026

Available online from October 28, 2026

Res.J. Pharmacology and Pharmacodynamics.2026;18(4):389-394.

DOI: 10.52711/2321-5836.2026.00052

©A and V Publications All right reserved

 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.